Literature DB >> 21228426

Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis.

Federico Alghisi, Paolo Palma, Enza Montemitro, Stefania Bernardi, Giuseppe Pontrelli, Paolo Rossi, Vincenzina Lucidi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21228426     DOI： 10.1136/thx.2010.156018

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  3 in total

1.  Influenza vaccination in children at high risk of respiratory disease.

Authors:  Maria Francesca Patria; Claudia Tagliabue; Benedetta Longhi; Susanna Esposito
Journal:  Ther Adv Vaccines       Date:  2013-05

2.  Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.

Authors:  Markus Knuf; Geert Leroux-Roels; Hans Rümke; Luis Rivera; Paola Pedotti; Ashwani Kumar Arora; Maria Lattanzi; Dorothee Kieninger; Giovanni Della Cioppa
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.

Authors:  Iván Bihari; Gyula Pánczél; Jozsef Kovacs; Jenny Beygo; Elena Fragapane
Journal:  Clin Vaccine Immunol       Date:  2012-10-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.